← Beam Therapeutics Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Net loss | ($78.3m) | ($194.6m) | ($370.6m) | ($289.1m) | ($132.5m) | ($376.7m) | ($80.0m) | — | |
| Depreciation and amortization | $3.5m | $4.7m | $7.5m | $14.1m | $20.0m | $21.9m | $22.3m | $22.2m | |
| Amortization of investment discount (premiums) | ($920k) | $118k | ($75k) | ($9.4m) | ($29.7m) | ($22.8m) | ($16.0m) | — | |
| Amortization of operating lease right-of-use assets | — | — | — | $8.4m | $9.5m | $9.7m | — | — | |
| Stock-based compensation expense | $7.0m | $15.4m | $43.6m | $84.3m | $98.6m | $120.7m | $94.2m | $81.5m | |
| Change in fair value of non-controlling equity investments | — | ($517k) | ($17.7m) | ($20.2m) | $18.6m | $14.1m | ($3.9m) | — | |
| Gain on sale of equity method investment | — | — | — | — | $0 | $0 | ($255.1m) | — | |
| Proceeds from sale of equity method investment | — | — | — | — | $0 | $0 | $255.1m | — | |
| Accounts payable | $4.1m | $60k | $818k | $2.4m | ($7.6m) | $1.8m | $6.0m | $3.0m | |
| Property and equipment additions in accounts payable and accrued expenses | $2.5m | $5.1m | $9.3m | $5.8m | $1.4m | $834k | $1.3m | — | |
| Accrued expenses and other liabilities | $3.6m | $7.0m | $43.9m | ($16.9m) | $67.7m | ($57.7m) | $7.7m | — | |
| Deferred revenue | — | — | $348.2m | ($35.9m) | ($159.6m) | ($36.5m) | ($135.4m) | — | |
| Other | — | ($517k) | $63k | $3k | — | — | — | — | |
| Prepaid expenses and other current assets | ($1.3m) | ($5.7m) | $746k | ($7.8m) | ($6.5m) | ($5.3m) | $4.5m | — | |
| Net cash provided by (used in) operating activities | ($72.0m) |
($95.7m)
-32.97%
|
($66.3m)
+30.78%
|
$22.5m
+133.99%
|
($149.2m)
-762.29%
|
($347.2m)
-132.75%
|
($345.1m)
+0.62%
|
($359.4m)
-4.14%
|
|
| Purchases of property and equipment | ($12.5m) | ($16.4m) | ($46.8m) | ($49.0m) | ($33.7m) | ($8.9m) | ($14.9m) | ($13.4m) | |
| Equipment financings, net | ($464k) | ($1.6m) | ($2.1m) | ($2.3m) | ($2.3m) | ($485k) | $0 | — | |
| Non-cash contribution of intellectual property to Orbital Therapeutics Inc. | — | — | — | $25.5m | — | — | — | — | |
| Realized loss (gain) on sale of marketable securities | — | — | — | — | $0 | $0 | $399k | — | |
| Purchases of marketable securities | ($129.8m) | ($281.6m) | ($777.2m) | ($1.6b) | ($984.3m) | ($486.4m) | ($1.2b) | — | |
| Maturities of marketable securities | $76.1m | $198.6m | $529.3m | $1.2b | $1.1b | $680.4m | $842.5m | — | |
| Proceeds from sale of marketable securities | — | — | — | — | $0 | $0 | $5.7m | — | |
| Net cash provided by (used in) investing activities | ($66.7m) | ($100.1m) | ($294.1m) | ($461.3m) | $71.8m | $185.0m | ($121.4m) | $189.5m | |
| Net cash provided by (used in) financing activities | $41.3m |
$322.3m
+680.84%
|
$756.1m
+134.59%
|
$111.6m
-85.24%
|
$276.4m
+147.74%
|
$7.7m
-97.20%
|
$478.0m
+6079.54%
|
$107.7m
-77.47%
|
|
| Cash, cash equivalents and restricted cash-beginning of year | $50.6m | $177.0m | $572.7m | $245.5m | $444.6m | $290.1m | $301.6m | — | |
| Net change in cash, cash equivalents and restricted cash | ($97.4m) | $126.5m | $395.7m | ($327.2m) | $199.1m | ($154.5m) | $11.5m | — | |
| Additional Supplementary Disclosures | |||||||||
| Additional Supplementary Disclosures | |||||||||
| In-process research and development charge | — | — | $155.0m | — | $0 | $0 | $14.5m | — | |
| Change in operating lease right-of-use assets | $1.9m | $4.7m | $9.0m | $8.4m | $9.5m | $9.7m | $10.4m | — | |
| Change in fair value of derivative liabilities | $5.4m | $63.4m | $1.0m | ($23.9m) | ($7.5m) | ($2.3m) | ($700k) | — | |
| Change in fair value of contingent consideration liabilities | — | — | ($5.1m) | $18.9m | ($9.7m) | ($1.6m) | ($180k) | — | |
| Other long-term assets | ($634k) | ($154k) | ($197k) | — | — | — | — | — | |
| Operating lease liabilities | ($2.5m) | $3.2m | $16.0m | $12.4m | ($10.2m) | ($13.0m) | ($13.5m) | — | |
| Collaboration receivable | — | — | ($300.0m) | $300.0m | ($146k) | — | — | — | |
| Other long-term liabilities | ($191k) | $981k | $1.8m | ($2.6m) | ($194k) | $473k | ($330k) | — | |
| Cash paid for acquisition, net | — | — | — | — | $0 | $0 | ($78k) | — | |
| Net cash acquired from Guide | — | — | $620k | — | — | — | — | — | |
| Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs | — | — | — | — | $235.9m | $0 | $470.5m | — | |
| Proceeds from issuance of common shares, net of commissions | — | $127.0m | $757.4m | $108.3m | $236.6m | — | — | — | |
| Proceeds from issuances of stock under ESPP | — | — | — | $3.1m | $3.0m | $2.6m | $2.8m | — | |
| Payment of equity offering costs | ($2.5m) | ($2.1m) | ($8.8m) | ($188k) | ($631k) | — | — | — | |
| Proceeds from exercise of stock options | $185k | $3.2m | $9.6m | $2.7m | $6.1m | $5.6m | $4.8m | — | |
| Proceeds from private stock issuance | — | — | — | — | $33.6m | $0 | $0 | — | |
| Cash paid for interest | $187k | $561k | $567k | $376k | $160k | $32k | $0 | — | |
| Operating lease liabilities arising from obtaining right-of-use assets | $6.2m | $74.7m | $25.9m | $41.0m | $3.9m | ($1.6m) | $6.2m | — | |
| Contingent consideration liabilities assumed in acquisition | — | — | $36.5m | — | $0 | $0 | $7.7m | — | |
| Fair value of equity instruments issued in connection with acquisition | — | — | — | — | $0 | $0 | $6.7m | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.